Extract
A 49-year-old male ex-smoker was referred for recurrent chest infections requiring one course of antibiotics every winter, occurring over the last 20 years. Each episode is characterised by a productive cough with purulent sputum along with difficulty breathing, chest tightness and fatigue, but without haemoptysis. On some occasions, these symptoms were preceded by fever and rhinorrhoea. Each episode lasted ∼10 days and responded well to antibiotics. He had never been hospitalised for these infections, nor received a chest radiograph or sputum microbiology. He had been told that he developed episodes of pneumonia in his first year of life. Apart from these yearly infections, the patient was asymptomatic during the rest of the year.
Abstract
Mounier-Kuhn Syndrome (MKS) is a rare disease characterised by recurrent chest infections, and dilation of the trachea and main bronchi, most likely to due to atrophy of elastic fibres https://bit.ly/3azhDjr
Acknowledgement
We thank the patient for providing consent for writing this case report with unidentifiable information.
Footnotes
Author contributions: All co-authors made substantial contributions to the conception or design of the work, the acquisition, analysis or interpretation of data for the work, drafting the work, or revising it critically for important intellectual content, and final approval of the version to be published.
Conflict of interest: I. Satia reports a BMA James Trust Award given to the University of Manchester to complete part of his PhD; personal fees for educational talks given to GPs, sponsored by GSK and AstraZeneca; sponsorship for travel to the European Respiratory Society (ERS) International Congress (GSK and Chiesi) and the British Thoracic Society Winter Meeting (Chiesi); a grant from Merck Canada; and an ERS RESPIRE 3 Marie Curie Fellowship, all outside the submitted work.
Conflict of interest: B. Dua has nothing to disclose.
Conflict of interest: N. Singh has nothing to disclose.
Conflict of interest: K. Killian has nothing to disclose.
Conflict of interest: P.M. O'Byrne reports personal fees from the joint oversight committee of a LABA safety study, personal fees for consulting from AstraZeneca, GSK, Merck and Boehringer, and grants from AstraZeneca, Genentech and Merck, all outside the submitted work.
- Received March 20, 2020.
- Accepted March 25, 2020.
- Copyright ©ERS 2020
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.